Attached files
file | filename |
---|---|
EX-32.1 - CERTIFICATION - Impact Medical Solutions, Inc. | ex32_1.htm |
EX-31.1 - CERTIFICATION - Impact Medical Solutions, Inc. | ex31_1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
_________________________
FORM 10-Q
(Mark One)
x
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
||||||
For the quarterly period ended
|
March 31, 2011
|
||||||
OR
|
|||||||
o
|
TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
||||||
For the transition period from
|
to
|
||||||
Commission file number:
|
000-52117
|
||||||
ITECH MEDICAL, INC.
|
|||||||
(Exact Name of Registrant as Specified in Its Charter)
|
|||||||
Delaware
|
20-5153331
|
||||||
(State of Other Jurisdiction of Incorporation or
Organization)
|
(I.R.S. Employer Identification Number)
|
||||||
17011 Beach Blvd., Suite 900, Huntington Beach, CA
|
92647
|
||||||
(Address of Principal Executive Offices)
|
(Zip Code)
|
||||||
(714) 841-2670
|
|||||||
(Registrant’s Telephone Number, Including Area Code)
|
|||||||
(Former Name, Former Address and Former Fiscal Year, If Changed Since Last Report)
|
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange act of 1934 during the preceding 12 months (or such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x Yes o No
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). o Yes o No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” "non-accelerated filer" and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer
|
o
|
Accelerated filer
|
o
|
Non-accelerated filer
|
o
|
Smaller reporting company
|
x
|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). o Yes x No
State the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date. As of May 20, 2010, there were 37,280,001 shares of the registrant’s Common Stock issued and outstanding.
TABLE OF CONTENTS
Page
|
||
PART I – FINANCIAL INFORMATION
|
||
Item 1.
|
Financial Statements
|
2 |
Item 2.
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations
|
11 |
Item 3.
|
Quantitative and Qualitative Disclosures About Market Risk.
|
15 |
Item 4T.
|
Controls and Procedures
|
15 |
PART II – OTHER INFORMATION
|
||
Item 1.
|
Legal Proceedings
|
16 |
Item 1A.
|
Risk Factors
|
16 |
Item 2.
|
Unregistered Sale of Equity Securities and Use of Proceeds
|
16 |
Item 3.
|
Defaults Upon Senior Securities
|
16 |
Item 4.
|
Submission of Matters to a Vote of Security Holders
|
16 |
Item 5.
|
Other Information
|
16 |
Item 6.
|
Exhibits
|
16 |
SIGNATURES
|
17 |
1
PART I
FINANCIAL INFORMATION
Item 1. Financial Statements.
iTech Medical Solutions, Inc.
(A Development Stage Company)
Condensed Consolidated Balance Sheets (Unaudited)
March 31,
|
December 31,
|
|||||||
2011
|
2010
|
|||||||
ASSETS
|
||||||||
Current assets
|
||||||||
Cash
|
$ | 300,385 | $ | 983,292 | ||||
Other current assets
|
57,037 | 49,495 | ||||||
Total current assets
|
357,422 | 1,032,787 | ||||||
Furniture and equipment, net of accumulated depreciation
|
12,302 | 12,960 | ||||||
Patent, net of accumulated amortization
|
276,959 | 284,312 | ||||||
|
$ | 646,683 | $ | 1,330,059 | ||||
LIABILITIES AND SHAREHOLDERS' DEFICIT
|
||||||||
Current liabilities
|
||||||||
Loans from related parties
|
$ | 20,000 | $ | 184,967 | ||||
Note payable
|
34,613 | 34,613 | ||||||
Accounts payable
|
360,265 | 296,528 | ||||||
Accrued interest
|
233,983 | 234,873 | ||||||
Accrued vacation
|
116,117 | 96,386 | ||||||
Accrued salaries, bonuses and other payroll related items
|
1,262,860 | 1,269,841 | ||||||
Director compensation
|
98,750 | 83,750 | ||||||
Total current liabilities
|
2,126,588 | 2,200,958 | ||||||
Commitments and contingencies
|
- | - | ||||||
Shareholders' deficit
|
||||||||
Preferred stock, 10,000,000 shares authorized, $.0001 par value,
|
||||||||
no shares issued and outstanding
|
- | - | ||||||
Common stock, 100,000,000 shares authorized, $.0001 par value,
|
||||||||
37,276,336 and 36,703,836 shares issued and outstanding
|
||||||||
at March 31, 2011 and December 31, 2010, respectively
|
3,728 | 3,671 | ||||||
Additional paid-in capital
|
19,085,012 | 13,915,344 | ||||||
Deferred option and warrant costs
|
(224,749 | ) | (123,643 | ) | ||||
Deficit accumulated during the development stage
|
(20,343,896 | ) | (14,666,271 | ) | ||||
Total shareholders' deficit
|
(1,479,905 | ) | (870,899 | ) | ||||
$ | 646,683 | $ | 1,330,059 |
The accompanying notes are an integral part of these condensed financial statements.
2
iTech Medical Solutions, Inc.
(A Development Stage Company)
Condensed Consolidated Statements of Operations
(Unaudited)
Cumulative
|
||||||||||||
from inception
|
||||||||||||
(October 20,
|
||||||||||||
Three months
|
1997) to
|
|||||||||||
|
ended March 31,
|
March 31,
|
||||||||||
|
2011
|
2010
|
2011
|
|||||||||
Costs and expenses:
|
|
|
||||||||||
Research and development
|
$ | 231,554 | $ | 28,197 | $ | 1,721,702 | ||||||
Medical and clinical
|
98,139 | 66,241 | 1,761,661 | |||||||||
General and administrative
|
5,342,979 | 388,359 | 15,336,042 | |||||||||
Operating loss
|
(5,672,672 | ) | (482,797 | ) | (18,819,405 | ) | ||||||
Other income (expense):
|
||||||||||||
Interest expense
|
(2,754 | ) | (7,641 | ) | (1,513,711 | ) | ||||||
Interest income
|
100 | - | 433 | |||||||||
(2,654 | ) | (7,641 | ) | (1,513,278 | ) | |||||||
Loss before provision for taxes
|
(5,675,326 | ) | (490,438 | ) | (20,332,683 | ) | ||||||
Provision for taxes
|
2,299 | 921 | 11,213 | |||||||||
Net loss
|
$ | (5,677,625 | ) | $ | (491,359 | ) | $ | (20,343,896 | ) | |||
Basic and diluted net loss per share
|
$ | (0.15 | ) | $ | (0.02 | ) | ||||||
Basic and diluted weighted average number of common shares outstanding
|
37,006,642 | 26,691,733 | ||||||||||
Maximum number of common shares (not included in denominator of diluted loss per share calculation due to their anti-dilutive nature) attributable to exercise of :
|
||||||||||||
Outstanding options
|
3,913,600 | 2,953,600 | ||||||||||
Outstanding warrants (Series A-G)
|
24,791,543 | 14,710,463 |
The accompanying notes are an integral part of these condensed financial statements.
3
iTech Medical Solutions, Inc.
(A Development Stage Company)
Condensed Consolidated Statements of Cash Flows
(Unaudited)
Cumulative
|
||||||||||||
from inception
|
||||||||||||
(October 20,
|
||||||||||||
Three months
|
1997) to
|
|||||||||||
ended March 31,
|
March 31,
|
|||||||||||
2011
|
2010
|
2011
|
||||||||||
Cash flows from operating activities:
|
||||||||||||
Net loss
|
$ | (5,677,625 | ) | $ | (491,359 | ) | $ | (20,343,896 | ) | |||
Adjustments to reconcile net loss to net cash
|
||||||||||||
used by operating activities:
|
||||||||||||
Depreciation and amortization
|
8,189 | 9,089 | 297,147 | |||||||||
Loss on disposal of assets
|
44 | - | 2,014 | |||||||||
(Gain)/Loss on extinguishment of debt
|
106,450 | - | 190,382 | |||||||||
Amortization of loan discount
|
- | 2,908 | 1,235,164 | |||||||||
Issuance of common stock for services & interest
|
103,566 | - | 3,593,640 | |||||||||
Issuance of stock options and warrants for services
|
4,711,303 | 168,357 | 6,732,346 | |||||||||
Decrease (increase) in prepaid expenses
|
(7,542 | ) | (8,177 | ) | (57,037 | ) | ||||||
Increase (decrease) in accounts payable
|
63,737 | 6,589 | 372,265 | |||||||||
Increase (decrease) in accrued expenses
|
26,860 | 52,965 | 1,711,710 | |||||||||
Net cash used by operating activities
|
(665,018 | ) | (259,628 | ) | (6,266,265 | ) | ||||||
Cash flows from investing activities:
|
||||||||||||
Capital expenditures
|
(218 | ) | (3,617 | ) | (88,445 | ) | ||||||
Net cash used by investing activities
|
(218 | ) | (3,617 | ) | (88,445 | ) | ||||||
Cash flows from financing activities:
|
||||||||||||
Proceeds from loans from related parties
|
- | 125,000 | 527,015 | |||||||||
Proceeds from convertible debt
|
- | - | 452,991 | |||||||||
Proceeds from loans from others
|
- | - | 10,000 | |||||||||
Payments on note payable
|
(20,000 | ) | - | (85,387 | ) | |||||||
Issuance of common stock, net of costs
|
- | - | 5,738,668 | |||||||||
Net cash provided (used) by financing activities
|
(20,000 | ) | 125,000 | 6,643,287 | ||||||||
Effect of exchange rate changes
|
2,329 | 4,213 | 11,808 | |||||||||
Net increase (decrease) in cash
|
(682,907 | ) | (134,032 | ) | 300,385 | |||||||
Cash, beginning of period
|
983,292 | 146,477 | - | |||||||||
Cash, end of period
|
$ | 300,385 | $ | 12,445 | $ | 300,385 | ||||||
Non-cash investing and financing activities:
|
||||||||||||
Issuance of common stock & note payable for patent
|
$ | - | $ | - | $ | 500,000 | ||||||
Issuance of warrants with debt
|
$ | - | $ | - | $ | 830,539 | ||||||
Conversion of debt to equity
|
$ | 147,300 | $ | - | $ | 147,300 | ||||||
Issuance of stock for deferred services
|
$ | 212,100 | $ | - | $ | 212,100 |
The accompanying notes are an integral part of these condensed financial statements.
4
iTech Medical Solutions, Inc.
(A Development Stage Company)
Condensed Consolidated Statements of Shareholders’ Equity (Deficit)
From Inception (October 20, 1997) to March 31, 2011 (Unaudited)
Common Stock
|
Accumulated
|
|||||||||||||||||||||||
Additional
|
Deferred
|
During the
|
Total
|
|||||||||||||||||||||
Number
|
Paid-in
|
Option &
|
Development
|
Shareholders'
|
||||||||||||||||||||
of Shares
|
Total
|
Capital
|
Warrant Cost
|
Stage
|
Equity (Deficit)
|
|||||||||||||||||||
Initial capitalization
|
3,000,000 | $ | 1,500 | $ | 1,250 | $ | - | $ | - | $ | 2,750 | |||||||||||||
Net loss for 1997
|
- | - | - | - | (2,750 | ) | (2,750 | ) | ||||||||||||||||
Balance, December 31, 1997
|
3,000,000 | 1,500 | 1,250 | - | (2,750 | ) | - | |||||||||||||||||
Net loss for 1998
|
- | - | - | - | - | - | ||||||||||||||||||
Balance, December 31, 1998
|
3,000,000 | 1,500 | 1,250 | - | (2,750 | ) | - | |||||||||||||||||
Net loss for 1999
|
- | - | - | - | - | - | ||||||||||||||||||
Balance, December 31, 1999
|
3,000,000 | 1,500 | 1,250 | - | (2,750 | ) | - | |||||||||||||||||
Net loss for 2000
|
- | - | - | - | - | - | ||||||||||||||||||
Balance, December 31, 2000
|
3,000,000 | 1,500 | 1,250 | - | (2,750 | ) | - | |||||||||||||||||
Net loss for 2001
|
- | - | - | - | - | - | ||||||||||||||||||
Balance, December 31, 2001
|
3,000,000 | 1,500 | 1,250 | - | (2,750 | ) | - | |||||||||||||||||
Net loss for 2002
|
- | - | - | - | - | - | ||||||||||||||||||
Balance, December 31, 2002
|
3,000,000 | 1,500 | 1,250 | - | (2,750 | ) | - | |||||||||||||||||
Net loss for 2003
|
- | - | - | - | (181,023 | ) | (181,023 | ) | ||||||||||||||||
Shares issued for patent
|
8,000,000 | 4,000 | 396,000 | - | - | 400,000 | ||||||||||||||||||
Shares issued for cash net of share issue costs of $86,096
|
2,086,000 | 1,043 | 434,361 | - | - | 435,404 | ||||||||||||||||||
Balance, December 31, 2003
|
13,086,000 | 6,543 | 831,611 | - | (183,773 | ) | 654,381 | |||||||||||||||||
Net loss for 2004
|
- | - | - | - | (733,248 | ) | (733,248 | ) | ||||||||||||||||
Stock option costs
|
- | - | 5,009 | - | - | 5,009 | ||||||||||||||||||
Warrants issued with loans payable
|
- | - | 4,225 | - | - | 4,225 | ||||||||||||||||||
Shares issued for cash net of share issue costs of $17,602
|
895,000 | 448 | 561,950 | - | - | 562,398 | ||||||||||||||||||
Balance, December 31, 2004
|
13,981,000 | 6,991 | 1,402,795 | - | (917,021 | ) | 492,765 | |||||||||||||||||
Net loss for 2005
|
- | - | - | - | (1,496,992 | ) | (1,496,992 | ) | ||||||||||||||||
Stock warrant costs
|
- | - | 238,892 | (199,946 | ) | - | 38,946 | |||||||||||||||||
Amortization of stock warrant costs
|
- | - | - | 85,273 | - | 85,273 | ||||||||||||||||||
Warrants issued with loans payable
|
- | - | 16,450 | - | - | 16,450 | ||||||||||||||||||
Shares issued for services
|
60,160 | 30 | 60,130 | - | - | 60,160 | ||||||||||||||||||
Shares issued for cash net of share issue costs of $52,689
|
1,045,000 | 522 | 991,789 | - | - | 992,311 | ||||||||||||||||||
Balance, December 31, 2005
|
15,086,160 | $ | 7,543 | $ | 2,710,056 | $ | (114,673 | ) | $ | (2,414,013 | ) | $ | 188,913 |
The accompanying notes are an integral part of these condensed financial statements.
5
iTech Medical Solutions, Inc.
(A Development Stage Company)
Condensed Statements of Shareholders’ Equity (Deficit)
From Inception (October 20, 1997) to March 31, 2011 (Unaudited) (continued)
Common Stock
|
Accumulated
|
|||||||||||||||||||||||
Additional
|
Deferred
|
During the
|
Total
|
|||||||||||||||||||||
Number
|
Paid-in
|
Option &
|
Development
|
Shareholders'
|
||||||||||||||||||||
of Shares
|
Total
|
Capital
|
Warrant Cost
|
Stage
|
Equity (Deficit)
|
|||||||||||||||||||
Balance, December 31, 2005
|
15,086,160 | $ | 7,543 | $ | 2,710,056 | $ | (114,673 | ) | $ | (2,414,013 | ) | $ | 188,913 | |||||||||||
Shares issued for cash
|
517,305 | 259 | 517,046 | - | - | 517,305 | ||||||||||||||||||
Shares issed for services
|
50,000 | 25 | 49,975 | - | - | 50,000 | ||||||||||||||||||
Impact shares converted to Freedom 1 at 1 to 1
|
- | (6,262 | ) | 6,262 | - | - | - | |||||||||||||||||
Shares issued upon merger
|
200,000 | 20 | (20 | ) | - | - | - | |||||||||||||||||
Value of warrants issued
|
- | - | 1,101,523 | (430,046 | ) | - | 671,477 | |||||||||||||||||
Amortization of stock warrant costs
|
- | - | - | 500,062 | - | 500,062 | ||||||||||||||||||
Net loss for 2006
|
- | - | - | - | (2,077,147 | ) | (2,077,147 | ) | ||||||||||||||||
Balance, December 31, 2006
|
15,853,465 | 1,585 | 4,384,842 | (44,657 | ) | (4,491,160 | ) | (149,390 | ) | |||||||||||||||
Shares issued for services
|
625,000 | 63 | 454,937 | (455,000 | ) | - | - | |||||||||||||||||
Value of warrants issued
|
386,399 | (33,363 | ) | - | 353,036 | |||||||||||||||||||
Amortization of share, option and warrant costs
|
- | - | - | 145,583 | - | 145,583 | ||||||||||||||||||
Net loss for 2007
|
- | - | - | - | (1,263,489 | ) | (1,263,489 | ) | ||||||||||||||||
Balance, December 31, 2007
|
16,478,465 | 1,648 | 5,226,178 | (387,437 | ) | (5,754,649 | ) | (914,260 | ) | |||||||||||||||
Shares issued for cash, net of issuance costs of $30,000
|
400,001 | 40 | 269,960 | - | - | 270,000 | ||||||||||||||||||
Settlement of liability
|
100,000 | 10 | 69,990 | - | - | 70,000 | ||||||||||||||||||
Shares issued for services
|
1,790,000 | 179 | 468,321 | (356,000 | ) | - | 112,500 | |||||||||||||||||
Value of warrants issued
|
- | - | 398,182 | (185,636 | ) | - | 212,546 | |||||||||||||||||
Amortization of share, option and warrant costs
|
- | - | - | 316,992 | - | 316,992 | ||||||||||||||||||
Net loss for 2008
|
- | - | - | - | (1,589,500 | ) | (1,589,500 | ) | ||||||||||||||||
Balance, December 31, 2008
|
18,768,466 | 1,877 | 6,432,631 | (612,081 | ) | (7,344,149 | ) | (1,521,722 | ) | |||||||||||||||
Shares issued for services
|
3,621,023 | 362 | 1,207,162 | (373,216 | ) | - | 834,308 | |||||||||||||||||
Value of warrants issued
|
- | - | 628,788 | (450 | ) | - | 628,338 | |||||||||||||||||
Shares issued for cash
|
1,818,333 | 182 | 508,318 | - | - | 508,500 | ||||||||||||||||||
Shares issued upon conversion of debt
|
2,723,911 | 272 | 816,901 | - | - | 817,173 | ||||||||||||||||||
Amortization of share, option and warrant costs
|
- | - | - | 727,421 | - | 727,421 | ||||||||||||||||||
Cancellation of shares
|
(240,000 | ) | (24 | ) | 24 | - | - | - | ||||||||||||||||
Net loss for 2009
|
- | - | - | - | (3,413,454 | ) | (3,413,454 | ) | ||||||||||||||||
Balance, December 31, 2009
|
26,691,733 | $ | 2,669 | $ | 9,593,824 | $ | (258,326 | ) | $ | (10,757,603 | ) | $ | (1,419,436 | ) |
The accompanying notes are an integral part of these condensed financial statements.
6
iTech Medical Solutions, Inc.
(A Development Stage Company)
Condensed Statements of Shareholders’ Equity (Deficit)
From Inception (October 20, 1997) to March 31, 2011 (Unaudited) (continued)
Common Stock
|
Accumulated
|
|||||||||||||||||||||||
Additional
|
Deferred
|
During the
|
Total
|
|||||||||||||||||||||
Number
|
Paid-in
|
Option &
|
Development
|
Shareholders'
|
||||||||||||||||||||
of Shares
|
Total
|
Capital
|
Warrant Cost
|
Stage
|
Equity (Deficit)
|
|||||||||||||||||||
Balance, December 31, 2009
|
26,691,733 | $ | 2,669 | $ | 9,593,824 | $ | (258,326 | ) | $ | (10,757,603 | ) | $ | (1,419,436 | ) | ||||||||||
Warrants issued for shareholder compensation
|
- | - | 272,843 | - | - | 272,843 | ||||||||||||||||||
Stock options granted
|
- | - | 217,184 | - | - | 217,184 | ||||||||||||||||||
Shares issued for services
|
2,836,428 | 284 | 1,182,211 | (100,000 | ) | - | 1,082,495 | |||||||||||||||||
Shares issued for cash
|
6,675,675 | 668 | 2,449,332 | - | - | 2,450,000 | ||||||||||||||||||
Shares issued upon conversion of debt
|
312,500 | 31 | 124,969 | - | - | 125,000 | ||||||||||||||||||
Shares issued for shareholder compensation
|
187,500 | 19 | 74,981 | - | - | 75,000 | ||||||||||||||||||
Amortization of share, option and warrant cost
|
- | - | - | 234,683 | - | 234,683 | ||||||||||||||||||
Net loss for 2010
|
- | - | - | - | (3,908,668 | ) | (3,908,668 | ) | ||||||||||||||||
Balance, December 31, 2010
|
36,703,836 | 3,671 | 13,915,344 | (123,643 | ) | (14,666,271 | ) | (870,899 | ) | |||||||||||||||
Warrants issued
|
- | - | 81,099 | - | - | 81,099 | ||||||||||||||||||
Value of Series A & B warrant extension
|
- | - | 4,611,436 | - | - | 4,611,436 | ||||||||||||||||||
Stock options granted
|
- | - | 11,340 | - | - | 11,340 | ||||||||||||||||||
Shares issued for services
|
210,000 | 21 | 212,079 | (212,100 | ) | - | - | |||||||||||||||||
Shares issued upon conversion of debt
|
362,500 | 36 | 253,714 | - | - | 253,750 | ||||||||||||||||||
Amortization of share, option and warrant cost
|
- | - | - | 110,994 | - | 110,994 | ||||||||||||||||||
Net loss for Q1 2011
|
- | - | - | - | (5,677,625 | ) | (5,677,625 | ) | ||||||||||||||||
Balance, March 31, 2011
|
37,276,336 | $ | 3,728 | $ | 19,085,012 | $ | (224,749 | ) | $ | (20,343,896 | ) | $ | (1,479,905 | ) |
The accompanying notes are an integral part of these condensed financial statements.
7
iTech Medical, Inc.
(Formerly known as Impact Medical Solutions, Inc.)
(A Development Stage Company)
Notes to Unaudited Condensed Consolidated Financial Statements
March 31, 2011
1. Organization and summary of significant accounting policies
Organization and Line of Business
iTech Medical, Inc. (a development stage company) (the "Company"), was incorporated in Nevada on October 20, 1997. From October 1997 to September 2003, the Company was a shell corporation. On September 9, 2003, the Company acquired from MPR Health Systems, Inc., all of that company’s rights and assets, including a patent, relating to a medical information system called Muscle Pattern Recognition (“MPR”). Since 2003, the Company has been involved in the development and pre-market clinical testing of the MPR System.
On January 22, 2010 the Company entered into a research and development contract with Salus Research, Inc. (“Salus”), a Canadian entity owned by a Company officer and two members of the Company’s Board of Directors. Salus began conducting scientific research and experimental development activities in Canada ("SR&ED") and plans to claim for Canadian Scientific Research and Experimental Development tax credits. The Company funds 100% of these expenditures, is at risk for 100% of its losses and owns 100% of all scientific discoveries, and as a result is the party that is the primary beneficiary of the relationship as defined by FASB ASC 810-10-05. Salus has no other financing other than amounts received from the Company. The Company has determined Salus to be a variable interest entity. Starting in January 2010 the Company has consolidated the financial results of Salus for financial reporting purposes to comply with Accounting Principles Generally Accepted in the United States. All intercompany transactions have been eliminated in consolidation. During 2011, the Company remitted CND$277,000 to Salus to fund scientific research and experimental development and is obligated to remit an additional CND$175,000 through June 2011.
Interim periods
The accompanying unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and Regulation S-K. Accordingly, they do not include all of the information required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2011 are not necessarily indicative of results for any future period. These statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Form 10-K for the year ended December 31, 2010.
2. Loans from related parties
Goldman Note
On December 3, 2007, the Company borrowed $40,000 from Alan Goldman, an executive officer. This loan bears interest at 10% per annum with an original maturity date of March 3, 2008. As additional consideration for the loan, the Company issued to Mr. Goldman 40,000 Series B Warrants with a fair value of $14,126. On January 19, 2011 the Company paid $20,000 on this loan leaving a $20,000 balance which is due June 30, 2011.
8
2. Loans from related parties (con’t)
Cavandale Note
In 2004, the Company borrowed CDN$145,000 from Cavandale Corporation, a corporation owned by Donald W. Paterson, one of the directors. The loans bear interest at 10% per annum with an original maturity date of November 1, 2004. As additional consideration for the loan, the Company issued to Cavandale Corporation 211,270 Series A Warrants with a fair value of $4,225. On February 19, 2011, the loan was converted to 362,500 shares of common stock resulting in a loss on the transaction of $106,450 which is recorded as general and administrative expenses in the accompanying statement of operations.
3. Shareholders’ equity
Stock issuance
As mentioned in Note 2 above, on February 19, 2011, the Company issued 362,500 shares of common stock for conversion of the Cavandale note.
On February 1, 2011, the Company issued 210,000 shares of common stock to two vendors for services valued at $212,100. The value of these services will be amortized over the one year contract period with these vendors.
Warrants
On March 25, 2011, the Company extended the expiration dates of both the Series A and Series B common stock purchase warrants. The Series A expiration date was extended from June 30, 2011 to June 30, 2012 and the Series B expiration date was extended from December 31, 2011 to December 31, 2012.
As a result of the due date extensions, the 4,420,603 Series A and 7,424,858 Series B warrants outstanding were re-valued at $4,611,436 using the Black-Scholes method and the resulting expense is included in general and administrative expenses in the accompanying statement of operations. The following weighted average assumptions were used to calculate the re-valued warrants: term of 1.25 – 1.75 years; risk-free interest rate of 0.625%; volatility of 164% - 194%; and a weighted fair value of $.3621 - $.4055.
On March 25, 2011, the Board of Directors also agreed to issue 200,001 Series B warrants to replace the Series D warrants that had expired. These warrants were valued at $81,099 using the Black-Scholes method and the resulting expense is included in general and administrative expenses in the accompanying statement of operations. The following weighted average assumptions were used to calculate the newly issued warrants: term of 1.75 years; risk-free interest rate of 0.625%; volatility of 194%; and a weighted fair value of $.4055.
9
3. Shareholders’ equity (continued)
Outstanding options and warrants
Security Type
|
Balance, December 31, 2010
|
Additions
|
Balance, March 31, 2011
|
Exercise Price
|
Expiration Date
|
2003 Stock option plan
|
2,953,600
|
---
|
2,953,600
|
$.25
|
March 10, 2014
|
2008 Stock option plan
|
960,000
|
---
|
960,000
|
$.25
|
June 24, 2020
|
Series A warrants
|
4,420,603
|
---
|
4,420,603
|
$.50
|
June 30, 2012
|
Series B warrants
|
7,424,858
|
200,001
|
7,624,859
|
$1.00
|
December 31, 2012
|
Series C warrants
|
1,185,001
|
---
|
1,185,001
|
$1.25
|
September 1, 2012
|
Series D warrants
|
---
|
---
|
---
|
$.95
|
September 1, 2010
|
Series E warrants
|
2,480,000
|
---
|
2,480,000
|
$.30
|
December 31, 2012
|
Series F-1 warrants
|
4,000,000
|
---
|
4,000,000
|
$.40
|
August 31, 2013
|
Series F-2 warrants
|
2,675,675
|
---
|
2,675,675
|
$.60
|
August 31, 2013
|
Series F-3 warrants
|
1,000,000
|
---
|
1,000,000
|
$.75
|
February 28, 2014
|
Series F-4 warrants
|
1,000,000
|
---
|
1,000,000
|
$.80
|
February 28, 2014
|
Series G-1 warrants
|
---
|
---
|
---
|
$.60
|
October 31, 2014
|
Series G-2 warrants
|
---
|
---
|
---
|
$.75
|
October 31, 2014
|
Series G-3 warrants
|
---
|
---
|
---
|
$.80
|
October 31, 2014
|
Series G-4 warrants
|
405,405
|
---
|
405,405
|
$..37
|
August 31, 2013
|
4. Subsequent events
Management has reviewed transactions through the date these financial statements were available for issuance, noting the following subsequent events:
On April 7, the Company extended the expiration dates of the Series C common stock purchase warrants from September 1, 2011 to September 1, 2012.
On March 12, 2011, the Company extended the Phase II Election Period of the Stock Purchase Agreement (the "Agreement"), dated March 19, 2010 and amended March 22, 2010, with Revox Ventures, Ltd. to April 30, 2011. Under the original Agreement, as amended, the Phase II Election Period was the 60 day period commencing upon the date the Company filed its 510(k) application regarding our Muscle Pattern Recognition System with the United States Food and Drug Administration (which occurred on February 22, 2011. Since Revox Ventures did not exercise their option to proceed with the Phase II financing within the period called for in the March 12, 2011 extension agreement, the Agreement expired on April 30, 2011 in accordance with its terms.
On May 13, 2011, the Company issued 3,666 shares of common stock to a vendor for services valued at $1,246.
10
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations Forward-Looking Statements
All statements other than statements of historical fact included in this Report regarding the prospects of our industry or our prospects, plans, financial position or business strategy, may constitute forward-looking statements. In addition, forward-looking statements generally can be identified by the use of forward-looking words such as “may,” “will,” “expect,” “intend,” “estimate,” “foresee,” “project,” “anticipate,” “believe,” “plans,” “forecasts,” “continue” or “could” or the negatives of these terms or variations of them or similar terms. Furthermore, such forward-looking statements may be included in various filings that we make with the SEC or press releases or oral statements made by or with the approval of one of our authorized executive officers. Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot assure you that these expectations will prove to be correct. These forward-looking statements are subject to certain known and unknown risks and uncertainties, as well as assumptions that could cause actual results to differ materially from those reflected in these forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements contained herein, which reflect management’s opinions only as of the date hereof. Except as required by law, we undertake no obligation to revise or publicly release the results of any revision to any forward-looking statements. You are advised, however, to consult any additional disclosures we make in our reports to the SEC. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained in this Report.
General
iTech Medical, Inc. is a development stage company engaged in the research and commercial development of healthcare information systems and technologies.
The Company was incorporated in 1997 in Nevada as Impact Medical Solutions, Inc. On September 9, 2003, the Company acquired a patent from MPR Health Systems, Inc. for a patented medical information system called Muscle Pattern Recognition (“MPR”). In December 2006, the Company merged into its wholly owned subsidiary Freedom 1, Inc., a Delaware corporation, and effectively reincorporated into Delaware. The Company changed its name to iTech Medical Inc. in 2009.
Business
The Company is a development stage company engaged in the research and commercial development of healthcare information systems and technologies. To date, we have focused on developing a proprietary platform called Muscle Pattern Recognition (MPR), a unique clinical tool for the analysis of muscle function.
MPR is a non-invasive, proprietary technology platform that objectively analyzes muscle recruitment patterns of the neck and back - the coordinated engagement of muscle groups in order to perform specific body movements. We believe that the MPR test results provide comprehensive information regarding those muscle recruitment patterns that can assist the healthcare professional in the evaluation and treatment of neck and back injuries and illnesses. The results of an MPR evaluation are presented in a detailed report that we believe provides objective, clinically relevant evidence on the status of underlying biomechanical and neuromuscular integrity, or the overall health of the neck and back.
We believe that the capabilities of the MPR System are unique and that the system addresses an unmet market need for an objective, evidence-based test for the use of physicians and other health care professionals to better assess and manage patients with impaired musculoskeletal function. We believe the MPR System supports the cost-containment and risk management goals of insurers, Workers’ Compensation carriers, self-insured employers and managed care providers by providing objective evidence to help control the soaring health care costs associated with neck and back injuries.
11
Our success is dependent upon several factors, including establishing the efficacy of MPR in clinical trials, obtaining the necessary regulatory approvals to market MPR and maintaining sufficient levels of funding through public and/or private financing. ITM has not commercially marketed MPR in any market to-date.
Our Market. According to industry sources, back pain is one of the most common and significant musculoskeletal medical problems in the world. Back injuries are the leading cause of disability in the United States for people younger than 45 years of age and have been the most expensive health care problem for the 20 to 50 year-old age group. Eighty percent of adults seek care at some time for low back pain, and one third of all disability costs in the United States are due to low back disorders.
Our target markets for MPR include primary care physicians, neurologists, orthopedic surgeons, physical medicine and rehabilitation physicians and occupational medicine practitioners; the Workers’ Compensation market; the self-insured employer market, and; Health Maintenance Organizations (HMOs).
Trends and Drivers. We believe several trends have emerged in our market. These include a growing number of employers and payors who are seeking ways to quantify and reduce the costs associated with back injuries; the continuing need for objective information in medical-legal injury litigation; the growing need for measuring patient treatment effectiveness and managing patients to successful outcomes; an increase in health care purchaser and health care provider attention to injury prevention, and; an increase in patient awareness of diagnostic and treatment alternatives. We believe these trends will be beneficial to our company because they support the demand for clinically proven tools that can reduce the costs and improve the outcomes of patients with neck and back pain.
We also recognize that there is a continuing trend by third party payors to reduce overall health care expenditures, and this trend affects a significant portion of our market. If we can demonstrate positive results in our clinical trial, our biggest challenge will be convincing the third party payors to accept the MPR system as a net savings rather than a net cost to the healthcare system.
Plan of Operation
In the next 12 months, we anticipate reaching a number of clinical, regulatory and commercial milestones. They include:
·
|
completing an international, multi-center Outcome Study;
|
·
|
obtaining clearance from the FDA to begin marketing and sales of the MPR System in the U.S.;
|
·
|
sign one or more distribution deals for the MPR System in North America and/or Europe; and,
|
·
|
begin sales in North America and Europe.
|
There are many challenges that we will encounter as we build our business. To meet these challenges, we believe it is important to assemble a team of experienced healthcare executives and medical opinion leaders to work with us to carry out the business and marketing plans of the Company. We also believe that to be successful in the development and commercialization of the MPR System, we must not only meet the milestones discussed above, but we must also:
·
|
Develop an awareness of MPR with physicians, employers, insurance companies, HMOs and other potential users of the MPR System;
|
·
|
Establish strong clinical and financial evidence of the key MPR value propositions through formal clinical studies representing our two target markets: North America and Europe;
|
·
|
Develop a template for consistent usage patterns of MPR in key reference accounts;
|
12
·
|
Establish a Reimbursement Support Services Team to assist our customers in their submissions for insurance reimbursement during the early stages of MPR market adoption;
|
·
|
Form relationships with key strategic partners with access to insurers, self-insured employers and other health care organizations that could use the MPR System;
|
·
|
Establish MPR in selected key reference accounts in geographic markets throughout Europe and the U.S., creating a delivery system to perform the tests as and where needed; and,
|
·
|
Form corporate alliances for the development, sales and marketing of MPR in a number of important yet opportunistic foreign markets that do not currently fall within our targeted geographic markets.
|
Funds currently available to us will not be adequate for us to complete these programs. We had $300,385 cash on hand as of March 31, 2011 however as of May 15, 2011, we had a negative cash balance of $8,657. We are in the development stage and have not earned any revenue since our inception. Therefore, we will need to raise additional funds in order to fully implement our business plan. However, there can be no assurance that we will be successful in raising such additional funds on favorable terms if at all. Regardless of whether our cash assets prove to be inadequate to meet our operational needs, we might seek to compensate providers of services by issuance of stock in lieu of cash.
Our continued operations therefore will depend upon our ability to raise additional funds through bank borrowings, equity or debt financing. Given the turbulence and volatility in the capital markets, there is no assurance that we will be able to obtain additional funding when needed, or that such funding, if available, can be obtained on terms acceptable to us. If we cannot obtain needed funds, we may be forced to curtail or cease our activities. We may encounter difficulty in obtaining these funds and/or credit lines. Moreover, even if additional financing or credit lines were to become available, it is possible that the cost of such funds or credit would be high and possibly prohibitive.
Results of Operations
Revenues. We have not generated any revenues since our inception on October 20, 1997.
Cash and Cash Equivalents. At March 31, 2011, we had $300,385 cash and cash equivalents on hand compared to $983,292 at December 31, 2010. This decrease was due to increased expenses incurred in our research and development activities.
Total Assets. At March 31, 2011, we had total assets of $646,683 compared to $1,330,059 at December 31, 2010. This decrease was primarily due to a decrease in cash and cash equivalents and to the amortization of our patent.
Total Liabilities. At March 31, 2011, we had total current liabilities of $2,126,588 compared to $2,200,958 at December 31, 2010. This decrease was primarily due to a decrease in loans payable.
Research and Development. For the three months ended March 31, 2011, we had research and development expenses of $231,554 compared to $28,197 for the three months ended March 31, 2010. The increase in spending was primarily due to an increase in staff related to the research and development of the MPR System.
Medical and Clinical Expenses. For the three months ended March 31, 2011, we had medical and clinical expenses of $98,139 compared to $66,241 for the three months ended March 31, 2010. This increase was primarily due to the costs incurred in the design of our clinical trial program for 2011.
General and Administrative Expenses. For the three months ended March 31, 2011, we had general and administrative expenses of $5,342,979 compared to $388,359 for the three months ended March 31, 2010. This increase was due to non-cash expenses of $4,611,436 related to the extension of our Series ‘A’ and Series ‘B’ Warrants; $81,099 related to the issuance of new Series ‘B’ warrants; $11,340 related to the amortization of stock options; $7,428 related to warrant amortization; and an increase in the issuance of common stock for services valued at $103,566.
13
Operating Losses. For the three months ended March 31, 2011, we had an operating loss of $5,672,672, compared to $482,797 for the three months ended March 31, 2010. This increase was due to non-cash expenses of $4,611,436 related to the extension of our Series ‘A’ and Series ‘B’ Warrants; $81,099 related to the issuance of new Series ‘B’ warrants; $11,340 related to the amortization of stock options; $7,428 related to warrant amortization; an increase in the issuance of common stock for services valued at $103,566, and an increase in research and development and clinical affairs expenses.
Net Loss. For the three months ended March 31, 2011, we had a net loss of $5,677,625 compared to $491,359 for the three months ended March 31, 2010. This increase was due to non-cash expenses of $4,611,436 related to the extension of our Series ‘A’ and Series ‘B’ Warrants; $81,099 related to the issuance of new Series ‘B’ warrants; $11,340 related to the amortization of stock options; $7,428 related to warrant amortization; an increase in the issuance of common stock for services valued at $103,566, and an increase in research and development and clinical affairs expenses.
Liquidity and Capital Resources
We continue to develop and enhance the features and performance of our technology with the goal of introducing new products based on our research and development activities. Eight of our thirteen employees and one of our independent consultants devote at least a portion of their time to research and development activities.
For the three months ended March 31, 2011 and March 31, 2010, we incurred a net loss of $5,677,625 and $491,359, respectively. At March 31, 2011, we had $300,385 cash on hand, as compared to $983,292 at December 31, 2010. At March 31, 2011, we had a stockholders’ deficit of $1,479,905 as compared to $870,899 at December 31, 2010.
We had $300,385 cash on hand as of March 31, 2011 however as of May 15, 2011, we had a negative cash balance of $8,657. We will need to raise additional capital to support our projected increases in staffing and other operating expenses, which we cannot give any assurance we will be able to accomplish. If we are unable to raise additional capital, it will be necessary for us to significantly reduce expenses to stay in business. In addition, any new equity or debt financing that we secure may not be available to us at prices that would be acceptable. Our failure to reduce expenses or obtain necessary financing could impair our ability to stay in business.
Financings
There were no financings during the quarter ended March 31, 2011.
Critical Accounting Policies
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. We rely on historical experience and on other assumptions we believe to be reasonable under the circumstances in making our judgment and estimates. Actual results could differ from those estimates. We consider our critical accounting policies to be those that are complex and those that require significant judgments and estimates, including the following: recognition of revenue, expensing of software development costs and valuation of our intangible assets and the determination of the valuation allowance of our deferred income taxes.
Long Lived Assets
Long-lived assets (primarily furniture and equipment and patents) are reviewed annually for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Impairment is necessary when the undiscounted cash flows estimated to be generated by the asset are less than the carrying amount of the asset.
Research and Development Costs
Costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with ASC 730, “Research and Development”.
14
Share-based Compensation
We have adopted the provisions of ASC 718 and have measured compensation cost related to stock options issued to employees at their fair value using the Black-Scholes method. Share-based payments issued to persons other than employees is also reflected in the financial statements at fair value computed using the Black-Scholes method.
Item 3. Quantitative and Qualitative Disclosures about Market Risk.
N/A
Item 4. Controls and Procedures.
Disclosure Controls and Procedures
Under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, our management evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act), as of the end of the period covered by this Annual Report on Form 10-K (the “Evaluation Date”). Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of the Evaluation Date, our disclosure controls and procedures are effective to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934 is (i) recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms and (ii) accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.
Management’s Report on Internal Control Over Financial Reporting
iTech Medical’s management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Exchange Act. As required by Rule 13a-15(c) under the Exchange Act, iTech Medical’s management carried out an evaluation, with the participation of iTech Medical’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of its internal control over financial reporting as of the end of the last fiscal year. The framework on which such evaluation was based is contained in the report entitled “Internal Control—Integrated Framework” issued by the Committee of Sponsoring Organizations of the Treadway Commission (the “COSO Report”).
iTech Medical’s system of internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Based on its assessment, management has concluded that iTech Medical maintained effective internal control over financial reporting as of December 31, 2010, based on criteria in “Internal Control - Integrated Framework” issued by the COSO.
Change in Internal Controls
There has been no change in our internal control over financial reporting that occurred during our last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
15
PART II
OTHER INFORMATION
Item 1. Legal Proceedings.
None.
Item 1A. Risk Factors.
N/A
Item 2. Unregistered Sale of Equity Securities and Use of Proceeds.
None.
Item 3. Defaults upon Senior Securities.
None.
Item 4. Submission of Matters to a Vote of Security Holders.
None.
Item 5. Other Information.
Item 6. Exhibits.
EXHIBIT INDEX
Exhibit No.
|
|
Description
|
31.1
|
|
Certification of the Company’s Principal Executive Officer and Chief Financial Officer pursuant to Section 302 of Sarbanes Oxley Act of 2002, with respect to the registrant’s Report on Form 10-Q for the quarter ended March 31, 2011.
|
32.1
|
Certification of the Company’s Principal Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002.
|
16
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: May 20, 2011
|
ITECH MEDICAL, INC.
|
|||
By:
|
/S/ WARREN G. BAKER
|
|||
Warren G. Baker
|
||||
President, Chief Executive Officer
|
||||
/S/ WAYNE D. COCKBURN
|
||||
Wayne D. Cockburn
|
||||
Chief Financial Officer
|
17